Finvest
NKTR Biotechnology · Clinical stage · Immunotherapy · High risk · Thesis updated July 15, 2026

Rezpeg now carries the Nektar story

01 Running thesis

A Phase 3 bet on immune reset

Nektar is now mostly a bet on REZPEG. The drug is designed to boost regulatory T cells, which are immune cells that help calm the body when the immune system is overactive. In atopic dermatitis, a serious form of eczema, Phase 2b data showed meaningful skin improvement and durability on less frequent dosing.

The bull case is clear. Nektar has started ZENITH-AD, a global Phase 3 program in moderate-to-severe atopic dermatitis. The company says first topline Phase 3 data are expected in mid-2028, with a planned FDA biologics license application in 2029 if the data work. REZPEG also showed statistically significant improvement in asthma control scores among atopic dermatitis patients with asthma, which could matter because DUPIXENT is one of the few drugs known for helping across related allergic diseases.

Alopecia areata adds upside, but it is not clean. The Phase 2b REZOLVE-AA trial missed statistical significance at week 36, with p values of 0.186 and 0.121. The later blinded extension helped repair the story, because 29% and 31% of continuing patients in the 18 and 24 mcg/kg arms reached new SALT Score 20 responses between weeks 36 and 52, while placebo had no new responses.

The bear case is timing and competition. Nektar must run large trials, compete with well-known biologics, and convince doctors to switch or add a new immune approach. The balance sheet gives it time, but the valuation score is weak because investors are being asked to price in success years before any possible commercial launch.

Jul 2026▲Nektar announced the start of the ZENITH-AD Phase 3 program for REZPEG in atopic dermatitis. That turns the core thesis from a planned Phase 3 story into an active execution story.
May 2026→The Q1 2026 filing showed $1,069.1 million of net financing proceeds from July 2025 through April 2026, which strengthened the runway. It also disclosed a new putative class action tied to REZOLVE-AA statements.
May 2026▲Management said cash and investments were more than $1 billion after the April financing. Alopecia areata also looked more salvageable after the 52-week extension showed new SALT Score 20 responses in treated patients.
Mar 2026→The 2025 Form 10-K gave a mixed REZPEG update. Atopic dermatitis durability improved the bull case, while the 36-week alopecia areata miss raised clinical risk.
Mar 2026▲Nektar raised about $476 million after year-end and said it could move quickly into Phase 3 for atopic dermatitis. Management also laid out a mid-2028 data goal and a 2029 filing target.
Nov 2025→The Q3 2025 filing added more atopic dermatitis data from EADV and noted the ATM facility was exhausted. It also added delay risk around the Eli Lilly litigation trial.
Aug 2025▲The Q2 2025 filing confirmed that REZOLVE-AD met its primary endpoint at week 16 across all three dose arms. FDA Fast Track designations in atopic dermatitis and alopecia areata also improved the regulatory setup.
02 Business model

Cash funds trials, not sales

Nektar does not yet have a normal product-sales business. It is a clinical-stage research company, so its value comes from drug candidates moving through trials and, later, possible approvals or partnerships. Today, the key spending need is Phase 3 development for REZPEG.

The company regained full rights to REZPEG after Eli Lilly ended their collaboration. That gives Nektar more control and more upside if the drug works, but it also means Nektar must carry more of the cost and execution risk itself.

The funding picture changed in a big way. From July 2025 to April 2026, Nektar sold common stock and pre-funded warrants for $1,069.1 million in net proceeds. Management said cash and investments were more than $1 billion after the April financing, with runway into the third quarter of 2028.

That cash cushion lowers near-term financing risk, but it came through equity issuance. Existing shareholders were diluted. The main business question is whether the Phase 3 data can create enough value to justify that dilution and the current price.

03 Product portfolio

One lead drug, several shots

Growth engine

REZPEG in atopic dermatitis

This is Nektar's main program. ZENITH-AD started in July 2026 and is expected to produce first topline data in mid-2028.

Option

REZPEG in alopecia areata

The first 36-week Phase 2b readout missed its main goal, but the 52-week extension showed new SALT Score 20 responses in about 30% of continuing treated patients. Nektar plans a Phase 3 start in early 2027.

Option

REZPEG in new onset type 1 diabetes

TrialNet is running a Phase 2 study in new onset stage 3 type 1 diabetes. Nektar supplies the drug and keeps rights to REZPEG.

Option

NKTR-255

NKTR-255 is the lead oncology candidate. It gives Nektar a cancer immunotherapy option, but the current stock story is much more tied to REZPEG.

Option

NKTR-0165 and NKTR-0166

These are early-stage autoimmune pipeline candidates. They may matter later, but they do not yet carry the same weight as REZPEG.

04 Business segments

No real sales mix yet

Autoimmune pipeline programs75%growing fast
Oncology pipeline programs25%flat

Nektar reports as a clinical-stage research business, not as a company with commercial revenue segments. The mix shown below is a pipeline bucket view from the 2025 Form 10-K named programs, not a revenue split.

05 Risk factors

What can break the case

ZENITH-AD fails or looks too ordinary

High impact · Medium odds

The main value driver is REZPEG in atopic dermatitis. If Phase 3 does not confirm the Phase 2b benefit, or if safety looks worse in larger trials, the stock thesis would change fast. Even a positive trial could disappoint if the effect does not look strong enough versus established drugs.

We watchZENITH-AD week 24 IGA 0/1, EASI-75, EASI-90, itch, safety, and maintenance data.

Doctors stay with entrenched biologics

High impact · Medium odds

DUPIXENT is already a major atopic dermatitis drug and has a strong position with doctors. REZPEG may need to prove durability, convenient dosing, and benefit in related conditions like asthma to win share. A new mechanism alone is not enough if doctors see no clear reason to switch.

We watchPhase 3 durability results, asthma subgroup data, dosing schedule, and any head-to-head or real-world positioning.

Alopecia areata path stays uncertain

Medium impact · Medium odds

REZOLVE-AA missed its week 36 primary endpoint. The 52-week extension helped, but regulators may still ask for a harder or longer trial package. If the FDA does not accept a single Phase 3 trial with a 52-week primary endpoint, cost and timing could rise.

We watchThe end-of-Phase 2 meeting outcome for alopecia areata and the final Phase 3 design.

Litigation becomes a bigger drag

Medium impact · Medium odds

Nektar is in litigation with Eli Lilly over the ended REZPEG collaboration. It also faces a putative class action filed in March 2026 that alleges misleading statements tied to the REZOLVE-AA trial. Legal cases may not decide the science, but they can add cost, distraction, and headline risk.

We watchCourt rulings, trial dates, settlement news, and any new disclosure tied to Schramke v. Nektar Therapeutics.

Cash runs out before approval

High impact · Low odds

The latest capital raises lowered near-term funding risk, with runway into the third quarter of 2028. That still may not cover a full path to launch if trials expand, data are delayed, or approval takes longer than planned. More financing could dilute shareholders again.

We watchQuarterly cash burn, runway guidance, Phase 3 trial costs, and any new equity financing.
06 Quick answers

In one breath

What does Nektar Therapeutics do?

Nektar develops medicines that change how the immune system acts. Its lead drug, REZPEG, is being tested mainly for autoimmune diseases such as atopic dermatitis and alopecia areata.

Why is REZPEG important for NKTR stock?

REZPEG is the center of the company story. If Phase 3 atopic dermatitis data are strong, Nektar could have a valuable new biologic, but weak data would hurt the thesis.

When could Nektar have Phase 3 data?

Nektar expects first topline data from the ZENITH-AD Phase 3 program in mid-2028. If the results support approval, the company is targeting a biologics license application in 2029.

Is Nektar profitable now?

No. Nektar is a clinical-stage biotech, so it is spending cash to run trials rather than earning steady product revenue.